NICE technology appraisal guidance
Issued: August 2011
TA233

Golimumab for the treatment of ankylosing spondylitis

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta233

1 Guidance

1.1 Golimumab is recommended as an option for the treatment of severe, active ankylosing spondylitis in adults only if:

  • it is used as described for adalimumab and etanercept in 'Adalimumab, etanercept and infliximab for ankylosing spondylitis' (NICE technology appraisal guidance 143) and

  • the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose in accordance with the patient access scheme.

1.2 People currently receiving golimumab for the treatment of severe, active ankylosing spondylitis who do not fulfil the criteria for treatment with adalimumab and etanercept described in NICE technology appraisal guidance 143 should have the option to continue golimumab until they and their clinician consider it appropriate to stop.